Early ADHD trial shows potential for orexin agonist

Alkermes' early-stage ADHD treatment trial shows potential

Alkermes is testing an orexin agonist for ADHD in early-stage trials, showing potential to address the condition. This represents a step toward possible future treatments, but the current stage means no proven efficacy or clinical impact exists yet. While reducing ADHD-related healthcare burden could eventually free up resources for millions, this signal remains early research with no immediate abundance implications. The source material is thin and details sit with the original report.

Source: STAT